Who Supplies Acarbose to India from GERMANY

To import Acarbose formulations into India, the following approvals are required:

1. Registration Certificate (Form 41): The foreign manufacturer must obtain a Registration Certificate for the drug and the manufacturing site. This involves submitting Form 40 to the Central Drugs Standard Control Organization (CDSCO), along with detailed information about the manufacturer, product, and compliance with Good Manufacturing Practices (GMP).

2. Import License (Form 10): An Indian entity, such as a pharmaceutical company or distributor, must apply for an Import License by submitting Form 8 to the CDSCO. This application should include the Registration Certificate and other relevant documents.

3. No Objection Certificate (NOC): In certain cases, an NOC from the Drug Controller General of India (DCGI) may be required, especially if the product is a new drug or has specific regulatory considerations.

The timeline for obtaining these approvals can vary, typically ranging from several months to over a year, depending on the completeness of the application and the specific requirements for Acarbose formulations under HS Code 30049099.

Quality control measures for imported Acarbose formulations include:

1. Mandatory Testing: Each batch must undergo testing at CDSCO-approved laboratories to verify compliance with prescribed standards.

2. Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the batch's quality parameters, must accompany each shipment.

3. Stability Data: Stability studies should be conducted under conditions specific to India's climate (ICH Zone IV) to ensure the product's efficacy and safety throughout its shelf life.

4. Pharmacopoeial Standards: Imported formulations must comply with the Indian Pharmacopoeia standards. If the product adheres to other pharmacopoeias like USP, BP, or EP, equivalence must be demonstrated.

5. Port of Entry Inspection: Upon arrival, customs drug inspectors may conduct inspections to ensure compliance with regulatory requirements before the product is released into the market.

Between 2024 and 2026, several policy changes have impacted the import of pharmaceutical formulations into India:

1. Minimum Import Price (MIP): In July 2025, the Indian government introduced an MIP on certain pharmaceutical raw materials to protect the domestic industry from low-cost imports. While this primarily targets raw materials, it may indirectly affect the cost structure of imported finished formulations.

2. Production-Linked Incentive (PLI) Scheme: The PLI scheme, aimed at boosting domestic manufacturing, has led to increased scrutiny of imported finished formulations to encourage local production.

3. Bilateral Agreements: As of March 2026, there have been no specific bilateral agreements between India and Germany affecting the import of pharmaceutical products.

Importers should stay informed about these regulatory changes to ensure compliance and adapt their import strategies accordingly.

India's importation of finished pharmaceutical formulations containing Acarbose from Germany is minimal, with a recorded import value of $99 USD from a single shipment. This limited import activity suggests that domestic production capacity for Acarbose formulations is sufficient to meet the country's demand. Acarbose is primarily used in the management of type 2 diabetes mellitus, a condition with a significant prevalence in India. The domestic pharmaceutical industry appears capable of producing the necessary Acarbose formulations, reducing the need for imports.

Under HS Code 30049099, which covers various pharmaceutical products, India's import duty structure is as follows:

• Basic Customs Duty (BCD): 10%
• Social Welfare Surcharge (SWS): 10% of the BCD
• Integrated Goods and Services Tax (IGST): 12%

Calculating the total landed duty:

1. 1BCD: 10% of the assessable value
2. 2SWS: 10% of BCD (i.e., 1% of the assessable value)
3. 3IGST: 12% of the sum of the assessable value, BCD, and SWS

This results in a cumulative duty impact of approximately 23.536% on the assessable value of the imported goods. No specific exemptions or concessional duties under Free Trade Agreements (FTAs) with Germany are currently applicable to this HS code.

Germany's role as a supplier of Acarbose formulations to India is minimal, with only one recorded shipment valued at $99 USD. This suggests that Germany's competitive advantage in this sector is limited. The Indian pharmaceutical industry, known for its robust manufacturing capabilities and cost-effective production, likely fulfills the majority of domestic demand for Acarbose formulations. Consequently, imports from Germany and other countries remain negligible.

India's importation of finished pharmaceutical formulations containing acarbose from Germany is primarily driven by the need for specialized dosage forms and high-quality standards that may not be widely available domestically. German manufacturers, such as MERCKLE GMBH, are known for producing advanced formulations, including modified-release tablets, which offer improved patient compliance and therapeutic efficacy. These specialized products often require sophisticated manufacturing technologies and stringent quality control measures, ensuring consistent bioavailability and stability. Additionally, certain acarbose formulations may be under patent protection or produced under technology licenses held by German companies, limiting their production to specific manufacturers. Consequently, Indian pharmaceutical companies and healthcare providers import these specialized formulations to meet the therapeutic needs of patients requiring specific acarbose products not readily manufactured within India.

When comparing Germany to other countries as a source of finished acarbose formulations, several factors come into play:

• Quality Perception and Regulatory Compliance: German pharmaceutical products are globally recognized for their high quality and adherence to stringent regulatory standards. The European Medicines Agency (EMA) enforces rigorous guidelines, ensuring that products meet safety and efficacy requirements. This reputation provides confidence to importers regarding product reliability.

• Supply Reliability: German manufacturers have established robust supply chains, ensuring consistent availability of pharmaceutical products. This reliability is crucial for maintaining uninterrupted treatment regimens for patients.

• Price Considerations: While German products may come at a premium compared to generic formulations from countries like China, the cost is often justified by the superior quality, advanced formulations, and regulatory compliance. In contrast, Chinese manufacturers may offer more cost-effective generic versions, but concerns regarding quality control and regulatory adherence can arise.

Germany's unique advantage lies in its ability to provide high-quality, specialized acarbose formulations that meet stringent regulatory standards, offering assurance to healthcare providers and patients alike.

Relying on Germany as a primary source for acarbose formulations presents several supply chain risks for Indian importers:

• Single-Source Dependency: Dependence on a single country or manufacturer increases vulnerability to supply disruptions. Any production issues or regulatory actions affecting the German supplier can lead to shortages.

• Currency Fluctuations: Exchange rate volatility between the Euro and the Indian Rupee can impact procurement costs, affecting pricing strategies and profit margins.

• Regulatory Changes: Modifications in German or European Union pharmaceutical regulations can affect production processes, compliance requirements, and export policies, potentially disrupting supply chains.

• Quality Incidents: Although rare, any quality control issues or product recalls involving German-manufactured acarbose can lead to supply interruptions and necessitate finding alternative sources.

• Shipping Disruptions: Global events, such as pandemics or geopolitical tensions, can disrupt international shipping routes, leading to delays or increased transportation costs.

To date, there have been no significant reported supply shortages of acarbose formulations imported from Germany into India. However, the potential risks underscore the importance of proactive supply chain management strategies.

To mitigate the aforementioned risks and ensure a stable supply of acarbose formulations, Indian pharmaceutical companies should consider the following strategies:

1. Dual-Sourcing Strategy: Establish relationships with multiple suppliers from different regions to reduce dependency on a single source. This approach enhances supply chain resilience and provides alternatives in case of disruptions.

2. Inventory Planning: Maintain adequate buffer stock to cushion against potential supply delays. Regularly review inventory levels and adjust procurement schedules based on demand forecasts and supplier lead times.

3. Flexible Payment Terms: Negotiate payment terms that accommodate potential currency fluctuations and economic uncertainties. Options such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) can provide financial flexibility.

4. Minimum Order Quantities (MOQs): Collaborate with suppliers to determine MOQs that balance cost-effectiveness with inventory management needs. Understanding supplier production constraints can aid in planning and negotiations.

5. Supplier Qualification Process: Implement a rigorous supplier evaluation and qualification process, including audits and quality assessments, to ensure compliance with regulatory standards and product specifications. Regular performance reviews can help maintain quality and reliability.

By adopting these strategies, Indian pharmaceutical companies can enhance their procurement processes, mitigate supply chain risks, and ensure a consistent supply of high-quality acarbose formulations to meet patient needs.

To legally import Acarbose formulations into India, follow these steps:

Before importing Acarbose formulations, ensure the German supplier provides the following documents:

Upon arrival of Acarbose formulations at an Indian port, the following quality assurance procedures are conducted:

To maintain compliance after importation, Indian importers should:

By meticulously following these guidelines, Indian importers can ensure the lawful and efficient importation of Acarbose formulations from Germany, maintaining the highest standards of pharmaceutical quality and compliance.